People who buy gray-market retatrutide aren't experiencing the same amount of weight loss as actual trial participants.
Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight…
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly…
Retatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval…
A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity,…
Eli Lilly says retatrutide helped obesity trial participants lose up to 28.3% body weight in the Phase 3 TRIUMPH-1 study.
Eli Lilly's weight loss drug retatrutide helped nearly half of participants in a phase 3 trial to lose more than 30% of their…
